Cover Image
市場調查報告書

奈米醫藥趨勢:技術基準&創新者分析

Trends in Nanomedicine - Technology Benchmarking & Innovator Analysis

出版商 Technical Insights (Frost & Sullivan) 商品編碼 348553
出版日期 內容資訊 英文 108 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
奈米醫藥趨勢:技術基準&創新者分析 Trends in Nanomedicine - Technology Benchmarking & Innovator Analysis
出版日期: 2015年12月30日 內容資訊: 英文 108 Pages
簡介

持續開發接續的新治療,隨著人口動態和公共衛生疑慮而值得關注。尤其是奈米技術被視為是這10年間最有力的實行技術。

本報告提供奈米醫藥趨勢相關調查分析、技術概要與趨勢、產業模式、用途、產品開發、市場潛力、主要企業、技術基準等相關整體分析彙整。

第1章 摘要整理

  • 調查的範圍
  • 調查方法
  • 主要調查結果

第2章 技術概要與趨勢

  • 產業的價值鏈和商務 模式
  • 核心技術
  • 技術的進步
  • 主要的成長機會
  • 技術的協同效應和奈米生物科技
  • 技術藍圖
  • 產業的促進要素與抑制因素
  • 產業的技術、商務的課題
  • 市場促進要素與抑制因素
  • 技術的促進要素與抑制因素
  • 波特的五力分析

第3章 產業模式和目標用途

  • 奈米醫藥創新模式
  • 奈米醫藥的用途
  • 奈米醫藥的治療
  • 奈米醫藥的診斷
  • 奈米醫藥的再生醫療

第4章 產品的開發與市場潛力

  • 多市場區隔
  • 主要產業的現實
  • 開發平台
  • 產品:各開發階段
  • 全球市場
  • 產品平台

第5章 主要相關利益者分析

  • 上市產品
  • 北美的主要企業
  • 歐洲的主要企業
  • 亞太地區的主要企業
  • 智慧財產權

第6章 技術基準

  • 多標準方法
  • 結論
  • 免責聲明

第7章 附錄

  • 主要的聯絡處

第8章 關於FROST & SULLIVAN

目錄
Product Code: D6C0-01-00-00-00

Nano-based science paving the precision medicine era

The continued development of new treatments associated with the demographic trends and public health considerations is remarkable. Nanotechnology has been identified as one most relevant key enabling technologies of the last ten years, significantly impacting on many different biomedical developments in a broad spectrum of applications therapeutics, diagnostics, theranostics, medical imaging, regenerative medicine, life sciences research and biosciences, among many others. In fact, nanomedicine is present in all therapeutic areas, exhibiting a perceptible and extensive impact in the treatment and diagnosis of some most concerned diseases.

Innovation in nanomedicine fields has played a major role in the improvement of both length and quality of life during the present decade, appreciably advocated to reduce the disease burden for individuals and the society through completely new or improved diagnostic and therapeutic methods. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for nanomedicine on precision medicine topics.

Frost & Sullivan identified an unprecedented behavior in terms of innovation in nanomedicine fields, with notable acceptance in diagnostics, therapeutics, companion diagnostics, regenerative medicine, and many other applications that are undoubtedly linked to the concept of precision medicine. Nanomedicine enables personalized medicine approaches in many ways. As an instance, nano-based diagnostic tests or nano-imaging diagnosis may help to the stratification of patients and thereby to guarantee a most personalized, patient-centered therapy. In addition, clinical protocols become simpler, more efficient and less costly.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Research Scope
  • 2. Research Scope (continued)
  • 3. Research Methodology
  • 4. Key Findings

2. TECHNOLOGY SNAPSHOT AND TRENDS

  • 1. Industry Value Chain and Business Model
  • 2. Core Technology Applications
  • 3. Technology Evolution
  • 4. Core Growth Opportunities
  • 5. Technology Synergy and Nanobiotechnology
  • 6. Technology Roadmap
  • 7. Industry Drivers and Restraints
  • 8. Industry Technical and Business Challenges
  • 9. Market Drivers and Restraints
  • 10. Technology Drivers and Restraints
  • 11. Porter's Five Forces Analysis

3. INDUSTRY MODELS AND APPLICATIONS TARGETED

  • 1. Nanomedicine Innovation Model
  • 2. Nanomedicine Innovation Model (continued)
  • 3. Nanomedicine Innovation Model (continued)
  • 4. Nanomedicines Application Focus
  • 5. Nanomedicines Therapeutics Focus
  • 6. Nanomedicines Diagnostics Focus
  • 7. Nanomedicines Regenerative Medicine Focus

4. PRODUCT DEVELOPMENT AND MARKET POTENTIAL

  • 1. Nanomedicine Multiple Segmentation
  • 2. Nanomedicines Principal Industry Facts
  • 3. Nanomedicines Principal Industry Facts (continued)
  • 4. Nanomedicine Development Pipeline
  • 5. Nanomedicine Products by Developmental Phase
  • 6. Global Nanomedicine Market
  • 7. Global Nanomedicine Market (continued)
  • 8. Global Nanomedicine Market (continued)
  • 9. Product Pipeline
  • 10. Product Pipeline (continued)
  • 11. Product Pipeline (continued)
  • 12. Product Pipeline (continued)
  • 13. Product Pipeline (continued)
  • 14. Product Pipeline (continued)

5. KEY STAKEHOLDER ANALYSIS

  • 1. Nanomedicine Marketed Products
  • 2. Nanomedicine Marketed Products (continued)
  • 3. Nanomedicine Marketed Products (continued)
  • 4. Key Companies in North America
  • 5. Key Companies in North America
  • 6. Key Companies in North America (continued)
  • 7. Key Companies in North America (continued)
  • 8. Key Companies in North America (continued)
  • 9. Key Companies in North America (continued)
  • 10. Key Companies in North America (continued)
  • 11. Key Companies in North America (continued)
  • 12. Key Companies in North America (continued)
  • 13. Key Companies in North America (continued)
  • 14. Key Companies in North America (continued)
  • 15. Key Companies in North America (continued)
  • 16. Key Companies in North America (continued)
  • 17. Key Companies in North America (continued)
  • 18. Key Companies in North America (continued)
  • 19. Key Companies in North America (continued)
  • 20. Key Companies in Europe
  • 21. Key Companies in Europe (continued)
  • 22. Key Companies in Europe (continued)
  • 23. Key Companies in Europe (continued)
  • 24. Key Companies in Europe (continued)
  • 25. Key Companies in Europe (continued)
  • 26. Key Companies in Europe (continued)
  • 27. Key Companies in Asia Pacific
  • 28. Key Companies in Asia Pacific (continued)
  • 29. Intellectual Property
  • 30. Intellectual Property (continued)
  • 31. Intellectual Property (continued)

6. TECHNOLOGY BENCHMARKING

  • 1. Multicriteria Approach for Benchmarking
  • 2. Multicriteria Approach for Benchmarking (continued)
  • 3. Multicriteria Approach for Benchmarking (continued)
  • 4. Multicriteria Approach for Benchmarking (continued)
  • 5. Multicriteria Approach for Benchmarking (continued)
  • 6. Multicriteria Approach for Benchmarking (continued)
  • 7. Multicriteria Approach for Benchmarking (continued)
  • 8. Multicriteria Approach for Benchmarking (continued)
  • 9. Multicriteria Approach for Benchmarking (continued)
  • 10. Final Remarks
  • 11. Legal Disclaimer

7. APPENDIX

  • 1. Key Contacts
  • 2. Key Contacts (continued)
  • 3. Key Contacts (continued)
  • 4. Key Contacts (continued)
  • 5. Key Contacts (continued)
  • 6. Key Contacts (continued)
  • 7. Key Contacts (continued)
  • 8. Intellectual Property Sources
  • 9. Key Patents
  • 10. Key Patents (continued)
  • 11. Key Patents (continued)

8. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top